Digitizing molecular tumor boards provides shared access to clinical insights for more personalized patient care across institutions, regions and countries
Success story
Institut für Hämatopathologie Hamburg (HpH Hamburg), Germany
Founded in 2004, the Institute for Hematopathology Hamburg has become a key player in Germany’s healthcare system. Dedicated to advancing diagnostics and translating scientific progress into clinical practice, it specializes in leukemia, lymphoma and solid tumors as well as benign hematologic disorders. With a team of over 300 employees, the institute ensures high-quality, rapid and reliable diagnostics supporting hematologists and oncologists in therapy decisions.
navify® Clinical Hub for Tumor Boards enables secure and efficient collaboration at HpH Hamburg
Institut für Hämatopathologie Hamburg (HpH Hamburg) is among Germany’s leading institutes in the field of hematopathological diagnostics. In addition to conventional histology, HpH applies a broad and diversified diagnostic methodology that includes immunohistochemistry, immunophenotyping and molecular analyses. Molecular diagnostics also extend to analyses of solid tumors to enable personalized therapy.
Challenges in interpreting molecular pathology for oncology treatment
Oncologic diagnosis and treatment decisions based on molecular pathology findings are extremely complex. Issues include unknown mutations that require interpretation and decision making based on the latest medical knowledge, as well as a lack of suitable clinical decision platforms that support supraregional exchange and joint evaluation of molecular pathological findings.
In the past, molecular tumor boards lacked the capability to conduct a common, standardized data search. Too often, the result was lost time and missed opportunities to learn from and leverage the most current medical knowledge. Digital platforms such as navify Clinical Hub for Tumor Boards offer huge advantages by providing essential structure and convenient, shared access to the most up-to-date research and data—ultimately, improving collaboration across regions and specialties to help clinicians reach consensus on personalized patient care plans.
Enhancing collaboration and decision-making in oncology care
navify Clinical Hub for Tumor Boards enables secure and efficient collaboration between molecular pathologists, oncologists and other experts across institutions, regions and countries. Relevant patient data and assets are accessed on the secure platform, helping authorized experts make informed diagnosis and treatment decisions. Clinical decision support applications, such as Clinical Trial Match, provide clinical care teams with access to the most up-to-date medical knowledge.
Standardizing and streamlining multidisciplinary tumor board collaboration
navify Clinical Hub for Tumor Boards standardizes and optimizes the communication, preparation, presentation and documentation processes of the MTB Norddeutschland. All external participants, independent of a small clinic or a teaching hospital, can easily create a patient case that includes all necessary information and outlines points of discussion. For each patient case, a dedicated key opinion leader meets virtually with a multidisciplinary team in different MTB rooms highlighting specific expertise in different types of cancer or in different regions.
The value of network for molecular tumor boards
navify Clinical Hub for Tumor Boards enables multidisciplinary oncology care teams to work together more effectively. In this German-language video, Prof. Tiemann in Germany reflects on the past, present and future of molecular Tumor Boards and how the Institut für Hämatopathologie Hamburg (HpH) uses the solution to focus on patient care improvement.
- Not every digital product is available in all markets. The use of any third-party app is subject to a separate license agreement with the respective third-party app developer. Roche gives no warranties (express or implied) with regard to any third-party app. Third-party apps might not be available in your country. This website and its content may be accessible worldwide, Roche assumes no liability with regard to the access to the information, which may not be compatible with legislations or regulations in force in your country.